system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
regulatory data protection exclusivity (including, where applicable, pediatric exclusivity and/or orphan drug exclusivity) and/or any other exclusivity afforded by restrictions which prevent the granting by a Regulatory Authority of regulatory approval to market a Generic Version. 1.54 "Regulatory Filing" means all approvals, licenses, registrations, submissions and authorizations made to or received from a Regulatory Authority in a jurisdiction necessary for or in connection with the development, manufacture and/or commercialization of a pharmaceutical product, including any INDs, Marketing Approval Applications, Marketing Approvals, and Pricing and Reimbursement Approvals. 1.55 "Secondary Royalty Term" means on a Product-by-Product and country by country basis within the Ono Territory, the period commencing on the expiration of the Initial Royalty Term for such Product and continuing until the [ * ] of the expiration of the Initial Royalty Term for such Product in such country. 1.56 "Senior Executives" means the Executive Directors of each of Ono and Array. 1.57 "Subcontractor" means any Third Party to which a Party or its Affiliate may subcontract the performance of any activities undertaken in accordance with this Agreement, provided that for clarity any entity which is involved in the selling of Products and is responsible for booking sales of Products shall not be included within this definition. 1.58 "Sublicensee" means a Third Party that has been granted a right to market and sell a Product in the Ono Territory (and optionally, the additional right to Develop such Product) pursuant to Section 2.2; and "Sublicense" shall mean an agreement or arrangement granting such rights. As used 12 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. in this Agreement, "Sublicensee" shall not include a wholesaler, distributor or reseller of such Product, to the extent that Ono sells to such person the Product at supply prices, and the arrangement does not include royalty payments or other payments tied to the revenue such wholesaler, distributor or reseller receives upon resale of the Product, whether paid in arrears or as transfer price unless such payment structure is consistent to that applied by Ono for its other oncology products in the relevant country, and /or significant lump sum payments. 1.59 "Third Party" means any person, corporation, joint venture or other entity, other than Array, Ono and their respective Affiliates. 1.60 "Third Party Partner" means Pierre Fabre Medicament SAS ("PFM") and any other Third Party to which Array grants a license or sublicense, as applicable, under the Array Patents and Array Know How to market and sell Product(s) outside the Ono Territory, either with or without accompanying rights to Develop and/or Manufacture such Product(s). 1.61 "Valid Claim" means a claim of an issued and unexpired Patent (including the term of any patent term extension, supplemental protection certificate, renewal or other extension) which has not been held unpatentable, invalid or unenforceable in a final decision of a court or other government agency of competent jurisdiction from which no appeal may be or has been taken, and which has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 1.62 Additional Definitions. Each of the following terms shall have the meaning described in the corresponding section of this Agreement indicated below: 13 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Term Section Defined Term Section Defined Approved Clinical Study 4.4(a)(i) Infringement Actions 11.4(a) Arbitration Tribunal Array Array Indemnitees 17.3(a) Introduction 16.1 Infringing Product JCC Chairperson 11.3(a)(i) 3.3 Array Regulatory Filings 4.6(b) JDRC Chairperson 3.3 Audited Site 4.6(d)(ii) Joint Clinical Study Proposal 4.4(a) Auditor AZ 7.4 11.3(a)(ii) Joint Commercial Committee /JCC 3.2(a) AZ Agreement BEACON Clinical Study 11.3(a)(ii) 4.1(c) Joint Development and Regulatory Committee /JDRC 3.1(a) Blocking Patent 6.5 Joint Development Plan 4.4(a)(i) CAPA COLUMBUS Clinical Study Combination Study(ies) 4.6(d)(ii) 4.1(c) 4.5(b)(i) Liabilities Liaison Local Study(ies) 16.1 3.7 4.5(b)(i) Commercializing Party 2.3(a) Marketing Materials 5.1(c) Commercialization Plan 5.1(b) Materials 9.1(a) Committee 3.3 Medical Journal 10.4 Committee Dispute Competing Product 3.5(a) 8.2 NEMO Clinical Study [ * ] 4.1(c) 14.2(a)(ii) Confidential Information Declined Clinical Study Development Plan Dispute Domain Name 10.1 4.4(c)(i) 4.2(a) 17.3 12.6 Non-Performing Party Novartis Ono Ono Indemnitees Patient Sample 4.4(c)(i)(D) 4.1(c) Introduction 16.2 4.10 Drug Product Drug Substance 9.1(b) 9.1(b) Performing Party
"""

Extract the exact clause related to "Price Restrictions" from the excerpt above.

assistant: Not found.